Afalaza tabs #100

Afalaza user manual

You can buy Afalaza on this page

Release form, composition and packaging

Tablets for resorption from white to almost white color, flat-cylindrical shape, with risk and chamfer; The inscription MATERIA MEDICA is inscribed on the flat side, and the inscription AFALAZA is inscribed on the other flat side.
1 tab.
antibodies to endothelial NO synthase affinity purified 0.006 g *
antibodies to prostate-specific antigen, affinity-purified 0.006 g *
* applied to lactose in the form of a mixture of three active aqueous-alcoholic dilutions of the substance, diluted in 10012, 10030, 100200 times, respectively.
Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.

pharmachologic effect

Antibodies to prostate-specific antigen (PSA) affinity purified modify the functional activity of endogenous PSA, modified by benign prostatic hyperplasia, which is accompanied by an increase in the regulatory effect of this antigen on the functional and metabolic processes in the prostate tissue. Antibodies to PSA have a preventive and therapeutic effect in prostate adenoma.
Antibodies to endothelial NO synthase affinity-purified contribute to an increase in blood flow velocity in the vessels of the penis and prostate gland; has a protective effect on the endothelium (helps reduce vascular reactivity, reduce vascular spasm and improve peripheral microcirculation).
The combined use of components in the complex preparation Afalaza is accompanied by a synergistic effect: antibodies to endothelial NO synthase due to the endothelium action and improved vascularization enhance the antiproliferative and anti-inflammatory activity of antibodies to PSA. The synergistic effect is probably also due to nonspecific mechanisms that enhance intracellular signal transduction by diluting antibodies to endothelial NO synthase.
The complex use of Afalaza components helps to improve the quality of life of patients with benign prostatic hyperplasia (BPH) and prostatitis, reducing dysuric disorders and erectile dysfunction; has a vegetative stabilizing effect.
It has been experimentally shown that the drug has a pronounced anti-inflammatory and anti-edema effect. Afalaza helps to normalize the functional state of the prostate and lower urinary tract, improve urodynamic performance (decrease in residual urine, increase the maximum speed of urine), normalize PSA levels. The drug also contributes to the reduction of dysuric disorders, and in some cases - a moderate decrease in the volume of the prostate gland.
The combined use of components improves spermatological parameters (an increase in the concentration of sex hormones, the number of spermatozoa and their mobility, a decrease in the viscosity of the seminal fluid, the normalization of the secretion of the prostate gland); activates regenerative-repair processes in patients undergoing surgery for benign prostatic hyperplasia, reduces the likelihood of complications after surgery.

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow to evaluate the content of active components of the drug Afalaza in biological fluids, organs and tissues, which makes it technically impossible to study pharmacokinetics.

Indications for Afalaza

- Benign prostatic hyperplasia of stage I and II;
- as part of the treatment of acute and chronic prostatitis (as an anti-inflammatory and analgesic);
- dysuric disorders (frequent urge to urinate, difficulty urinating, pain and discomfort in the perineal region);
- Erectile dysfunction (erectile dysfunction) of different origin;
- vegetative menopausal disorders in men (weakness, fatigue, decreased physical activity, decreased libido, and others);
- as part of complex therapy used before and after surgical interventions on the prostate gland.

Contraindications

- increased individual sensitivity to the components of Afalaza.

Dosage

The drug is taken orally, 2 times / day, in the evening and in the morning. At one time - 2 tablets (to keep in the mouth until completely dissolved - not during the meal).
The recommended duration of Afalaza is 16 weeks.
With severe pain syndrome and dysuric disorders in the first 2-3 weeks of therapy, the drug is indicated to be taken up to 4 times / day.
If necessary, on the recommendation of a doctor, it is possible to repeat the course of treatment in 1-4 months.

Side effects

Possible reactions increased individual sensitivity to the components of Afalaza.

Overdose

In case of accidental overdose, dyspeptic symptoms are possible due to the fillers in the preparation.

Drug interaction

Cases of incompatibility with other drugs have not yet been registered.

special instructions for Afalaza

The preparation includes lactose monohydrate, and therefore it is not recommended to prescribe it to patients with congenital galactosemia, glucose or malabsorption malabsorption syndrome or galactose, or in congenital lactase deficiency.

Influence on ability to drive motor transport and control mechanisms

Afalaza does not affect the ability to drive vehicles and other potentially dangerous machinery.

Pregnancy and lactation

The drug Afalaza is not intended for use in women.

Pharmacy sales terms

You can buy Afalaza without a prescription.

Terms and conditions of storage

Afalaza should be stored out of the reach of children, protected from light at a temperature not higher than 25 ° C. Shelf life - 3 years. Do not use after the expiration date.